US Food and Drug Administration (USFDA) has completed inspection at Biocon’s Insulin Glargine Drug Substance, Drug Product and Device assembly facilities in Malaysia. A per-approval inspection by USFDA was carried out from June 24 and July 5, 2019. The inspection across these 3 units concluded with 12 observations issued on the Form 483.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.00 |
| Dr. Reddys Lab | 1224.00 |
| Cipla | 1231.40 |
| Zydus Lifesciences | 931.00 |
| Lupin | 2326.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: